Doctors have been left astonished after an experimental cancer drug caused every patient in a trial to enter remission.
The drug dostarlimab appeared to cure every patient during a clinical trial at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York.
The cancer drug was given to 18 people with a type of rectal cancer every three weeks for six months.